| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037184727 |
| P356 | DOI | 10.1186/S12933-016-0362-0 |
| P932 | PMC publication ID | 4804508 |
| P698 | PubMed publication ID | 27005817 |
| P5875 | ResearchGate publication ID | 299380792 |
| P2093 | author name string | Dan Liu | |
| Yaling Han | |||
| Xiaolin Zhang | |||
| Tengfei Liu | |||
| Chenghui Yan | |||
| Wenzhi Cai | |||
| Dingyu Zhang | |||
| P2860 | cites work | Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 |
| Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment | Q28199546 | ||
| Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? | Q28218910 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease | Q28222643 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| Tag SNP selection in genotype data for maximizing SNP prediction accuracy | Q30992243 | ||
| GEVALT: an integrated software tool for genotype analysis | Q33271462 | ||
| Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents | Q33335010 | ||
| A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial | Q34751965 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study | Q34910745 | ||
| The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study | Q35073622 | ||
| Insulin receptor substrate 1 (IRS1) variants confer risk of diabetes in the Boston Puerto Rican Health Study | Q35598032 | ||
| Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk | Q35609789 | ||
| Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study | Q35677083 | ||
| Platelet function monitoring in patients with coronary artery disease | Q36990868 | ||
| microRNAs and cancer: an overview | Q37249283 | ||
| Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions | Q37428365 | ||
| Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials | Q38005018 | ||
| Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes | Q38430548 | ||
| Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin | Q40693554 | ||
| Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia | Q43981677 | ||
| Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 | ||
| IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi | Q44645484 | ||
| Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study | Q44680472 | ||
| A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. | Q46528728 | ||
| A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis | Q46811912 | ||
| Platelet inhibition by insulin is absent in type 2 diabetes mellitus | Q46843983 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. | Q51628204 | ||
| Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Q57764490 | ||
| Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study | Q79685552 | ||
| Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy | Q82942386 | ||
| Pharmacogenetics in cardiovascular antithrombotic therapy | Q84541445 | ||
| Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses | Q85426083 | ||
| Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients | Q87861118 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | coronary artery disease | Q844935 |
| type 2 diabetes | Q3025883 | ||
| clopidogrel | Q410237 | ||
| P304 | page(s) | 50 | |
| P577 | publication date | 2016-03-22 | |
| P1433 | published in | Cardiovascular Diabetology | Q2468083 |
| P1476 | title | Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus | |
| P478 | volume | 15 |
| Q49908173 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease |
| Q38924963 | IRS proteins and diabetic complications |
| Q58795845 | Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting |
| Q42254531 | PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology |
| Q55471692 | Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. |
| Q37724614 | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives |
| Q39343342 | Platelets, diabetes and myocardial ischemia/reperfusion injury. |
| Q33818356 | Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. |
| Q57279877 | The role of insulin receptor substrate 1 gene polymorphism Gly972Arg as a risk factor for ischemic stroke among Indonesian subjects |
Search more.